[HTML][HTML] Overview of current systemic management of EGFR-mutant NSCLC
Front-line epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) therapy is
the standard of care for lung cancer patients with sensitising EGFR mutations (exon 19 …
the standard of care for lung cancer patients with sensitising EGFR mutations (exon 19 …
[HTML][HTML] Strategies to improve outcomes of patients with EGFR-mutant non–small cell lung cancer: review of the literature
C Zhou, L Di Yao - Journal of Thoracic Oncology, 2016 - Elsevier
Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) monotherapy has
been regarded as the standard first-line treatment of advanced non–small cell lung cancer …
been regarded as the standard first-line treatment of advanced non–small cell lung cancer …
Treatment of non-small cell lung cancer with EGFR-mutations
K Yoneda, N Imanishi, Y Ichiki, F Tanaka - Journal of UOEH, 2019 - jstage.jst.go.jp
The discovery of activating mutations in the epidermal growth factor receptor (EGFR) gene
and development of tyrosine kinase inhibitors (TKIs) of EGFR have achieved a paradigm …
and development of tyrosine kinase inhibitors (TKIs) of EGFR have achieved a paradigm …
Treatments for EGFR-mutant non-small cell lung cancer (NSCLC): the road to a success, paved with failures
DH Lee - Pharmacology & therapeutics, 2017 - Elsevier
The discovery of epidermal growth factor receptor (EGFR) activating mutations in non-small
cell lung cancer (NSCLC) and the success story of EGFR tyrosine kinases inhibitors (TKIs) …
cell lung cancer (NSCLC) and the success story of EGFR tyrosine kinases inhibitors (TKIs) …
Third generation EGFR TKIs in EGFR-mutated NSCLC: where are we now and where are we going
A Russo, T Franchina, GRR Ricciardi… - Critical reviews in …, 2017 - Elsevier
The therapeutic landscape of Non Small Lung Cancer (NSCLC) has been profoundly
changed over the last decade with the clinical introduction of Epidermal Growth Factor …
changed over the last decade with the clinical introduction of Epidermal Growth Factor …
Clinical outcomes in non‐small‐cell lung cancer patients with EGFR mutations: pooled analysis
L Paz‐Ares, D Soulières, I Melezínek… - Journal of cellular …, 2010 - Wiley Online Library
Introduction• Literature review‐Molecular biology of EGFR mutations‐Clinical characteristics
of NSCLC patients with EGFR mutations‐Genetic characteristics of EGFR‐mutated tumours …
of NSCLC patients with EGFR mutations‐Genetic characteristics of EGFR‐mutated tumours …
[HTML][HTML] Recent advances on the role of EGFR tyrosine kinase inhibitors in the management of NSCLC with uncommon, non exon 20 insertions, EGFR mutations
The first-line treatment of choice for patients with epidermal growth factor receptor (EGFR)
mutation-positive non-small cell lung cancer (NSCLC) is an EGFR tyrosine kinase inhibitor …
mutation-positive non-small cell lung cancer (NSCLC) is an EGFR tyrosine kinase inhibitor …
Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer
M Takeda, I Okamoto, K Nakagawa - Lung Cancer, 2015 - Elsevier
Objectives Three epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs)–
afatinib, erlotinib, and gefitinib–are available for the treatment of patients with EGFR …
afatinib, erlotinib, and gefitinib–are available for the treatment of patients with EGFR …
Therapeutic strategy for advanced EGFR mutant non-small-cell lung carcinoma
J Cadranel, AM Ruppert, M Beau-Faller… - Critical reviews in …, 2013 - Elsevier
Activating mutation in exons 19 or 21 of epidermal growth factor receptor (EGFR) in non-
small-cell lung cancers (NSCLC) are associated with increased sensitivity to EGFR tyrosine …
small-cell lung cancers (NSCLC) are associated with increased sensitivity to EGFR tyrosine …
Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non–small-cell lung cancer: a meta-analysis of 13 randomized trials
F Petrelli, K Borgonovo, M Cabiddu, S Barni - Clinical lung cancer, 2012 - Elsevier
Advanced non–small-cell lung cancer (NSCLC) harboring activating mutations of epidermal
growth factor receptor (EGFR) are particularly sensitive to tyrosine kinase inhibitors (TKIs) …
growth factor receptor (EGFR) are particularly sensitive to tyrosine kinase inhibitors (TKIs) …